Abstract 832P
Background
Treating pediatric acute B-cell lymphoblastic leukemia (pB-ALL) who experience central nervous system relapses (CNSR) is challenging and often results in high mortality rates. The aim of this study was to develop and validate a predictive model for CNSR in pB-ALL, allowing for early identification and assessment.
Methods
1495 patients of pB-ALL patients from the TARGET database were randomly assigned to a training cohort of 1079 patients and an internal validation cohort of 416 patients. Multi-variable COX regression analysis was applied to construct the model using the training cohort. The validation cohorts comprised of an internal validation cohort and an external validation cohort consisting of Chinese patients. The analysis was conducted using consistency index (C-index), AUROC, Kaplan-Meier curves, calibration curve, and decision curve analysis to evaluate this model.
Results
The prediction model for CNSR in pB-ALL, named CLOMB, was constructed using indicators selected from the training cohort. The model had a C-index of 0.748 and was found to be highly accurate in predicting CNSRs in both the training and validation cohorts, as determined by AUROC measures. A statistically significant difference in event-free survival was observed between pB-ALL patients divided into CNSR high-risk and low-risk groups using the CLOMB calculated risk score of 0.76 as a cut-off value. In the external validation cohort, CLOMB had an AUROC of 0.590, which was significantly higher than MRD on days 19 and days 46.
Conclusions
The newly developed predictive model, CLOMB, has shown strong power and utility in CNS relapse prediction and risk stratification, which may help modify treatment options in clinical routine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
212P - BRGSF-HIS mice as a predictive tool for safety assessment of biologics
Presenter: Kader Thiam
Session: Poster session 09
213P - Constructing a high-definition patient-digital twin (PDT) in treatment-naïve women with advanced cancer
Presenter: Leonardo Garma
Session: Poster session 09
215P - Detection of MUTYH for the prognosis and chemotherapy responsiveness of patients with non-small cell lung cancer
Presenter: Chi Wai Wong
Session: Poster session 09
216P - β-catenin is a potential prognostic biomarker in uterine sarcoma
Presenter: Ying Cai
Session: Poster session 09
218P - Exploiting a unique glycosaminoglycan for novel pan-cancer therapies and diagnostics
Presenter: Mette Agerbæk
Session: Poster session 09
219P - The landscape and prognostic impact of germline HLA-A subtypes in patients with advanced solid cancers
Presenter: Kyrillus Shohdy
Session: Poster session 09
220P - The role of fucosyltransferase 1 (FUT1) in CRC as a putative prognostic and predictive biomarker
Presenter: Lorenz Pammer
Session: Poster session 09
221P - ANGPTL4's role in cancer: A meta analysis and bioinformatics exploration
Presenter: Osama Younis
Session: Poster session 09
222P - Artificial intelligence (AI) based prognostication from baseline computed tomography (CT) scans in a phase III advanced non-small cell lung cancer (aNSCLC) trial
Presenter: Omar Khan
Session: Poster session 09